SEC Form 4 · accession 0001209191-18-044944
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pritesh Shah
Officer — Chief Commercial Officer
Period of report
Jul 31, 2018
Accepted (ET)
Aug 2, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $34.00 | Jul 31, 2018 | A | 20,458 | A | — | Jul 30, 2028 | Ordinary Shares | 20,458 | 20,458 | D |
| Restricted Stock UnitF2,F3 | — | Jul 31, 2018 | A | 11,152 | A | — | — | Ordinary Shares | 11,152 | 11,152 | D |
Explanation of responses
- F1Options to buy 20,458 ordinary shares will vest and become exercisable in equal installments on each of July 31, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- F2Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
- F3One-third of these restricted stock units are scheduled to vest on each of July 31, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates.